Oncology:
Rituximab:
Genetic polymorphism of the inhibitory IgG Fc receptor FcGR-2B is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. (N=101 rituximab-treated patients)
Weng and Levy, Leukemia & Lymphoma50:723-727. (2009)

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. (N=188 chemotherapy-treated patients)
Weng and Levy, Leukemia & Lymphoma50:1494-1500. (2009)

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. (N=87 rituximab-treated patients)
Weng and Levy, J. Clin. Oncology 21: 3940-3947. (2003)

Cetuximab:
Impact of FcGRIIa-FcGRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. (N=69 patients)
Bibeau et al., J. Clin. Oncology 27: 1122-1129. (2009)

Trastuzumab:
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer. (N=54 patients)
Musolino et al., J. Clin. Oncology 26:1789-1796. (2008)

Alemtuzumab:
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenström’s macroglobulinemia and mast cell disorders.
Santos et al., Clinical Lymphoma & Myeloma 6:478-483. (2006)

Lupus:
FcGR 2A, 3A, and 3B polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. (N=140 German SLE patients)
Manger et al., Ann. Rheumatic Diseases 61:786-792. (2002)

FcGR-2A alleles are heritable risk factors for lupus nephritis in African Americans. (N=257 SLE patients)
Salmon et al., J. Clin. Investigation 97:1348-1354. (1996)

FcG receptor polymorphisms in systemic lupus erythematosus. (N=230 SLE patients)
Dijstelbloem et al., Arthritis & Rheumatism 43:2793-2800. (2000).

Genetic linkage and association of FcGR-3A (CD16A) on Chromosome 1q23 with human systemic lupus erythematosus. (N=438 SLE patients)
Edberg et al., Arthritis & Rheumatism 46:2132-2140. (2002)

Identification of IgG subclasses and C-Reactive Protein in lupus nephritis (N=80 patients)
Zuniga et al., Arthritis & Rheumatism 48:460-470. (2003)

Decreased transcription of the human FcGR-2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. (N=391 ethnicity agnostic; N=190 European Americans)
Blank et al., Human Genetics 117:220-227. (2005)

MAb Theragnostics:
FDA holds court on post hoc data linking KRAS status to drug response.
Mack, GS., Nature Biotechnology 27:110-112 (2009)

Novel risk-sharing scheme puts the spotlight on biomarkers.
Hughes, B., Nature Reviews Drug Discovery 6:945 (2007)

Looking forward, looking back.
Editorial Commentary. Nature Biotechnology 26:475 (2008)

The emerging role of pharmacogenomics in biologics.
Lacana et al., Clinical Pharmacology & Therapeutics 82:466-471 (2007)

Payers aim to rein in specialty-drug spending: employers, health plans, PBMs push for legislation. Idea: ‘Pay for Performance’.
Chase M., Wall Street Journal page:B1, March 20, 2008.